Mersana Therapeutics to Speak at Investor Conferences

Mersana Therapeutics, Inc., a biopharmaceutical company in the clinical stages of developing antibody-drug conjugates (ADCs) aimed at cancers with high unmet medical needs, has announced its participation in two upcoming investor conferences.

Executives from Mersana will be presenting at the TD Cowen 5th Annual Oncology Innovation Summit and the Goldman Sachs 45th Annual Global Healthcare Conference. The format for both events will be a fireside chat. The first event is scheduled for Wednesday, May 29, 2024, at 9:00 a.m. Eastern Time, while the second will take place on Wednesday, June 12, 2024, at 8:00 a.m. Eastern Time.

Investors and interested parties will be able to watch live webcasts of these events, accessible via the Investors & Media section of Mersana's website. Recordings of the webcasts will remain available for approximately 90 days after the events.

Mersana Therapeutics is dedicated to creating novel ADCs and is motivated by the urgent need for new cancer therapies. The company has developed unique platforms, Dolasynthen and Immunosynthen, which are instrumental in producing both wholly-owned and collaborative product candidates. These candidates have the potential to address a variety of cancers. Two notable products in their pipeline are XMT-1660 and XMT-2056. XMT-1660 is a Dolasynthen ADC that targets B7-H4, while XMT-2056 is an Immunosynthen ADC that targets a unique epitope of the human epidermal growth factor receptor 2 (HER2).

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!